Skip main navigation

Home > Search Results

Main contents starts here

Search Results

1 - 20 of about 508

Total 508 documents found.

  •  
  • Takeda to Expand Presence in Asia with Operations in South Korea June 23, 2010
  • Osaka, Japan, June 23, 2010 – Takeda Pharmaceutical Company Limited (Osaka, Japan, “Takeda”) announced today it will establish a new commercial subsidiary in South Korea. Takeda aims to increase its global market coverage to approximately 90 percent by the end of fiscal 2012, one of the key strategic initiatives of the 2010-2012 Mid-Range Plan.
  • Approval of Additional Indications for Helicobacter pylori Eradication by Concomitant Therapy with Proton Pump Inhibitors June 18, 2010
  • Osaka and Tokyo, Japan, June 18, 2010 --- Takeda Pharmaceutical Company Limited (Osaka, President and CEO: Yasuchika Hasegawa), AstraZeneca K.K. (Osaka, President and CEO: Masahiro Kato), Mitsubishi Tanabe Pharma Corporation (Osaka; President and CEO: Michihiro Tsuchiya), and Eisai Co., Ltd. (Tokyo; President and CEO: Haruo Naito) jointly announced today that they have received approval from the Japanese Ministry of Health, Labor and Welfare for additional indications for Helicobacter pylori (“H. pylori”) eradication by concomitant therapy with three proton pump inhibitors, lansoprazole, omeprazole, and rabeprazole sodium, marketed in Japan under four brand names. This concomitant therapy consists of a proton pump inhibitor, amoxicillin hydrate, and either clarithromycin or metronidazole, and is indicated for the eradication of H. pylori in gastric MALT lymphoma(*1), idiopathic thrombocytopenic purpura(*2) (“ITP”) and the stomach after endoscopic resection of early stage gastric cancer.
  • Takeda to Continue Strategic Expansion with Operations in Brazil December 2, 2009
  • Osaka, Japan, December 2, 2009 – Takeda Pharmaceutical Company Limited (Osaka, Japan, “Takeda”) announced today it will establish a new commercial subsidiary in Brazil. The new subsidiary represents the 12th new strategic expansion since January 2009 including Canada, Spain, Portugal, Ireland, Mexico, Sweden, Norway, Denmark, Belgium, Luxembourg and Turkey.
  • Takeda Introduces ‘Cisco TelePresence’ (Advanced Videoconferencing System) September 10, 2009
  • Osaka, Japan, September 10, 2009 --- Takeda Pharmaceutical Company Limited (Head Office: Chuo-ku, Osaka; President: Yasuchika Hasegawa, “Takeda”) announced today that it has introduced Cisco TelePresence™, －an advanced videoconferencing system providing both high-resolution visuals and a high-quality audio environment. Cisco TelePresence™ was provided by Cisco Systems G.K. (Headquarters: Minato-ku, Tokyo; President & CEO: Edzard J.C. Overbeek, “Cisco”), and IBM Japan, Ltd. (Headquarters: Minato-ku, Tokyo; President: Takayuki Hashimoto; NYSE: IBM, “IBM Japan”) provided support to introduce this videoconfereincing system at Takeda. .
  • Takeda to Start Sales and Marketing Operation in Portugal May 7, 2009
  • Osaka, Japan & London, United Kingdom, May 7, 2009 – Takeda Pharmaceutical Company Limited (Osaka, Japan, “Takeda”) and its wholly-owned UK-based subsidiary for overseeing pan-European sales & marketing, Takeda Pharmaceutical Europe Limited (London, UK, “TPEU”) have jointly announced the start of their own wholly owned sales and marketing operation in Portugal, Takeda Farmacêuticos Portugal, Unipessoal, Lda (Lisbon, Portugal, “Takeda Portugal”). This represents the latest move in Takeda’s initiative to enhance its business infrastructure in Europe.
  • Takeda Expands its Own Sales and Marketing Operations in Europe March 30, 2009
  • Osaka, Japan & London, United Kingdom, March 30, 2009 – Takeda Pharmaceutical Company Limited (Osaka, Japan, “Takeda”) and its wholly-owned UK-based subsidiary for overseeing pan-European sales & marketing, Takeda Pharmaceutical Europe Limited (London, UK, “TPEU”) jointly announced today the start of its own sales and marketing operations in Spain, and also the expansion of its operations in the Republic of Ireland to cover the entire country, which used to be limited in a specific area.
  • CanBas and Takeda to Sign the Collaboration Agreement for Investigational Compounds for Treatment of Cancer March 30, 2007
  • Numazu and Osaka, Japan - March 30, 2007 --- CanBas Co., Ltd. (Numazu, Shizuoka, "CanBas") and Takeda Pharmaceutical Company Limited (Osaka, "Takeda") today announced that both parties signed the collaboration agreement for investiga- tional compounds for treatment of cancer, CBP501 and its backup compounds discovered by CanBas. With this agreement, the world-wide exclusive right for development, manufacturing and marketing is granted to Takeda, while in the U.S. the development and promotion are jointly conducted by both parties.
  • Termination of License Agreement for Tavocept™ in Japan November 2, 2006
  • Tokyo/Osaka, Japan, November 2, 2006 --- ASKA Pharmaceutical Co., Ltd. ("ASKA", Tokyo, Japan) and Takeda Pharmaceutical Company Limited ("Takeda", Osaka, Japan) announced the termination of the License Agreement of March 15, 2006 that had previously been entered into by Takeda, ASKA, KI Pharmaceuticals, Inc.(*) ("KI Pharma", Tokyo, Japan) and BioNumerik Pharmaceuticals, Inc. (San Antonio, Texas, "BioNumerik") with respect to the investigational new drug known as Tavocept™ for the territory of Japan. Tavocept™ (generic name: dimesna) is an investigational new drug with potential for oncology and non-oncology indications that was originated and developed by BioNumerik.
  • Takeda to Establish New Research Facility in Fujisawa, Japan October 25, 2006
  • October 25, 2006, Osaka, Japan --- Takeda Pharmaceutical Company Limited ("Takeda") today announced that it will establish new research facility in Fujisawa city, Kanagawa prefecture, integrating the current research facilities in Osaka city and Tsukuba city, Ibaragi prefecture. The new facility is planned to start the operation in fiscal year of 2010.
  • Takeda to Sponsor The LaSalle Bank Chicago Marathon October 12, 2006
  • Osaka, Japan and Deerfield, Ill. (October 12, 2006) − Takeda Pharmaceutical Company Limited, Osaka, Japan ("Takeda") and its wholly owned subsidiary, Takeda Pharmaceuticals North America, Inc., Deerfield, Ill. ("TPNA") announced today their official sponsorship of The LaSalle Bank Chicago Marathon, which will expand Takeda's commitment to endurance sports across the globe. A first−year sponsor of the Chicago race, Takeda has a history of marathon sponsorship in Japan.
  • Correction against Takeda Based on Transfer Pricing Taxation June 28, 2006
  • Osaka, Japan, June 28, 2006 --- Takeda Pharmaceutical Company Limited ("Takeda") today received a notice of correction based on transfer pricing taxation from the Osaka Regional Taxation Bureau ("ORTB") founded on the ORTB's conclusion that the profits earned in the US market in relation to product supply and license trans-actions between Takeda and TAP Pharmaceutical Products Inc., a fifty-fifty joint venture between Abbott Laboratories and Takeda America Holdings, Inc., a wholly owned subsidiary of Takeda in the US, over the six-year period from fiscal year ending March 2000 through fiscal year ending March 2005 were under-allocated to Takeda.
  • License Agreement for Tavocept™ in Japan March 16, 2006
  • Tokyo/Osaka, Japan, March 16, 2006 --- ASKA Pharmaceutical Co., Ltd. ("ASKA", Tokyo, Japan) and Takeda Pharmaceutical Company Limited ("Takeda", Osaka, Japan) announced today that both parties, KI Pharmaceuticals, Inc.(*) ("KI Pharma", Tokyo, Japan) and BioNumerik Pharmaceuticals, Inc. (San Antonio, Texas, "BioNumerik") have entered into a license agreement for Tavocept™(generic name: dimesna) in Japan.Tavocept™ is a chemoprotective agent originated and developed by BioNumerik.
  • Partial Transfer of Wyeth K.K. Equity from Takeda to Wyeth April 7, 2005
  • Madison N.J., U.S.A. and Osaka, Japan −−− Wyeth (Headquarters: Madison, N.J., U.S.A.; President, Chief Executive Officer and Chairman: Robert Essner, "Wyeth") and Takeda Pharmaceutical Company Limited (Headquarters:, Osaka; President:Yasuchika Hasegawa, "Takeda") agreed that Takeda, which holds a 40 percent share, would transfer a 10 percent share of Wyeth K.K. (Headquarters:, Tokyo; President: Rune Bremberg) to Wyeth with the transfer to be completed today.
  • Takeda to Transfer its Life-environmental Business to Osaka Gas March 30, 2005
  • OSAKA, JAPAN −−− Osaka Gas Co., Ltd. ("Osaka Gas", President: Hirofumi Shibano) and Takeda Pharmaceutical Company Limited ("Takeda", President: Yasuchika Hasegawa) jointly announced today the transfer of shares of Takeda's five subsidiaries and affiliates engaged in life-environmental business to Osaka Gas Chemicals Co., Ltd. ("Osaka Gas Chemicals", President: Mitsuo Endo), a subsidiary of Osaka Gas. Such five companies include Japan EnviroChemicals, Ltd. ("Japan EnviroChemicals" President: Atsuo Kobayashi), a wholly owned subsidiary of Takeda.

Pages:[1] [2] [3] [4] [5] [6] [7] [8] [9] [10]   Next

Page Top